Skip to main content
    V

    Verastem Inc (VSTM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.70
    -0.48 (-5.87%)

    Market Cap: $1.03B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Verastem Inc (VSTM) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Verastem are Vor Biopharma (VOR), Theravance Biopharma (TBPH) and Sarepta Therapeutics (SRPT). By market cap, Verastem ranks 9th of the 13 companies on this page; Vera Therapeutics (VERA) is the largest at $2.03B.

    Peer Comparison

    VSTM's ROIC of -110.4% is below the peer median of -50.8%, and its revenue growth of 113.6% is above the median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Verastem (VSTM)$1.03BN/A7.8x-178.4%-110.4%113.6%0.00%
    Vor Biopharma Inc (VOR)$1.19BN/AN/A0.0%N/A0.0%0.00%
    Theravance Biopharma Inc (TBPH)$884.18M95.1x8.4x51.6%N/A-20.9%0.00%
    Sarepta Therapeutics Inc (SRPT)$1.72BN/A0.8x-5.9%-3.2%-4.5%0.00%
    Nuvectis Pharma Inc (NVCT)$696.03MN/AN/A0.0%N/A0.0%0.00%
    Corvus Pharmaceuticals Inc (CRVS)$897.52MN/AN/A0.0%N/A0.0%0.00%
    Vera Therapeutics Inc (VERA)$2.03BN/A189.3x0.0%-83.0%0.0%0.00%
    Nuvation Bio Inc (NUVB)$1.41BN/A6.7x-67.4%-18.7%242.6%0.00%
    Structure Therapeutics Inc. American Depositary Shares (GPCR)$1.43BN/AN/A0.0%N/A0.0%0.00%
    Stoke Therapeutics Inc (STOK)$1.75BN/A64.5x0.0%N/A5.9%0.00%
    CureVac NV (CVAC)$1.05BN/A1.8x182.1%N/A-89.0%0.00%
    DBV Technologies (DBVT)$692.19MN/AN/A0.0%-130.3%-42.9%0.00%
    Vir Biotechnology Inc (VIR)$1.71BN/A5.4x-61.0%N/A19582.0%0.00%
    Peer median$1.30B95.1x6.7x0.0%-50.8%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Verastem, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Vor Biopharma Inc (VOR)
    Vor Biopharma, Inc., an early stage cell therapy company, develops hematopoietic stem cell (eHSC) therapies designed for cancer patients.
    VOR competitors
    Theravance Biopharma Inc (TBPH)
    Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe...
    Sarepta Therapeutics Inc (SRPT)
    Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapies, gene therapy...
    SRPT competitors
    Nuvectis Pharma Inc (NVCT)
    Nuvectis Pharma, Inc., a biopharmaceutical company, is focused on the development of targeted small molecule therapies for the treatment of cancer.
    NVCT competitors
    Corvus Pharmaceuticals Inc (CRVS)
    Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies.
    CRVS competitors
    Vera Therapeutics Inc (VERA)
    Vera Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immune diseases...
    VERA competitors
    Nuvation Bio Inc (NUVB)
    Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is focused on developing therapeutic candidates for oncology.
    NUVB competitors
    Structure Therapeutics Inc. American Depositary Shares (GPCR)
    Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic...
    GPCR competitors
    Stoke Therapeutics Inc (STOK)
    Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops new antisense oligonucleotide (ASO) drugs to treat the underlying causes of serious...
    STOK competitors
    CureVac NV (CVAC)
    CureVac NV, a clinical-stage biopharmaceutical company, is focused on developing various transformative drugs based on messenger ribonucleic acid (mRNA).
    DBV Technologies (DBVT)
    DBV Technologies SA, a clinical-stage biopharmaceutical company, is dedicated to the research and development of epicutaneous immunotherapy products.
    DBVT competitors
    Vir Biotechnology Inc (VIR)
    Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases.
    VIR competitors

    Frequently Asked Questions About VSTM

    Who are Verastem's main competitors?

    The companies most similar to Verastem include Vor Biopharma (VOR), Theravance Biopharma (TBPH), Sarepta Therapeutics (SRPT), Nuvectis Pharma (NVCT) and Corvus Pharmaceuticals (CRVS), listed from the closest match.

    Who is Verastem's biggest competitor?

    Vera Therapeutics (VERA) is the largest of the similar companies at $2.03B; Vor Biopharma (VOR) is the closest match by business profile, size, sector and industry.

    How does VSTM stock compare with its competitors?

    VSTM's P/S is 7.8x against a peer median of 6.7x; its net margin is -178.4% against a peer median of 0.0%.

    Which of Verastem's competitors pays a higher dividend?

    Verastem pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Verastem bigger than its competitors?

    No. Verastem is 9th by market cap among the 13 companies on this page; the largest is Vera Therapeutics (VERA) at $2.03B.